
News|Videos|March 12, 2025
RX Review: The role of needle-free epinephrine in pediatric allergy for 2025
In part 3 of this 5-part series, panelists discuss the recent Neffy approval, oral immunotherapy, and Xolair’s role in allergy management.
Advertisement
Advertisement
In this Contemporary Pediatrics and HCPLive RX Review discussion, moderator Brian Schroer, MD, speaks with Colleen Kraft, MD, and Russell Traister, MD, about the impact of needle-free epinephrine options, including epinephrine nasal spray (neffy) which received approval for treating type 1 allergic reactions in patients aged 4 years and older weighing at least 30 kg on March 5, 2025.1
Related to this article

In a matched cohort of children aged 6 and younger with EoE, dupilumab was linked to less incident asthma than swallowed budesonide (10.5% vs 16.2%).

The FDA approved once-weekly somapacitan-beco for growth failure in Turner syndrome in children aged 2.5+ years, based on phase 3 REAL8 data.

In a phase 2 trial, tofacitinib met its safety end point and lowered interferon and cytokine scores in adolescents and adults with Down syndrome.

The FDA approved oral venglustat for neurological symptoms of type 3 Gaucher disease in patients ≥15 kg, based on phase 3 LEAP2MONO data.

Eczema was linked to 28% higher odds of sleep disturbance in a 26,395-patient pediatric primary care cohort presented at ACAAI 2026.

Laura Tochen, MD, of Children's National Hospital, discusses how the first disease-modifying therapy for Alexander disease could change care and diagnosis.

At ACAAI 2026, 93.6% of pediatric biologic prescriptions needed prior authorization, 39.3% were denied, and approval took a mean of 33 days.
Advertisement
Advertisement

